Business Wire

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
MedPage Today

In NMOSD, Could Inhibiting Complement C5a Help Reduce Pain?

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
PR Newswire

Complement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsight

The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...
Business Wire

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced positive topline results from its Phase 1 single ascending dose (SAD) study in healthy participants of RLYB116, ...